Engflag

Fibrasol

Quick links to important sections

Fibrasol

Fibrasol_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fibrasol

Property Description
Active Ingredient Psyllium Hydrophilic Mucilloid
Form Powder or Granules
Pharmacological Class Bulk-Producing Laxative
Common Use Regulation of intestinal function
Origin Natural (Psyllium Husk from Plantago ovata)

What Type of Medicine is Fibrasol?

Fibrasol is an Over-The-Counter (OTC) pharmaceutical preparation categorized as a Bulk-Producing Laxative. This product is fundamentally designed for the normalization and regulation of intestinal function, promoting predictable and natural bowel movements. The mechanism of action places it distinctly apart from stimulant laxatives, as it functions through a gentle, mechanical process rather than the chemical irritation of the intestinal walls. The Fibrasol brand often distinguishes itself by providing the Psyllium Hydrophilic Mucilloid in convenient granules or a flavored powder format, focusing its positioning on consumer palatability and ease of consumption.

Active Ingredient and Natural Origin

The sole active ingredient in this formulation is Psyllium Hydrophilic Mucilloid, which is derived from the outer seed husks of the Plantago ovata plant, marking it as a natural source material. Psyllium is classified as a source of non-fermentable, soluble fiber, which gives it a powerful hydrophilic capacity. The product is typically presented in dosage forms such as powder or granules, which are intended for oral administration after mixing with a liquid vehicle. Research consistently supports the view that Psyllium's effect is localized within the gastrointestinal tract with minimal systemic absorption.

How Psyllium Works to Increase Bulk

The core functional principle relies on the hydrophilic ability of the Psyllium Hydrophilic Mucilloid to rapidly absorb water within the intestinal lumen. This rapid hydration and swelling create a soft, viscous gel-like mass that significantly increases stool bulk and ensures the fecal matter retains essential moisture. The resulting increase in fecal biomass is the primary action that promotes peristalsis, helping to regulate the overall transit time and consistency of the intestinal contents. This mechanical bulking action is key to its general function as a versatile regulator for bowel function.

What side effects are possible with Fibrasol?

Possible Side Effects and Safety Information

The safety profile of Fibrasol is primarily associated with its classification as a soluble dietary fiber, with adverse reactions generally being mild and related to gastrointestinal function. The product is widely utilized in food and beverage formulations and has been studied for its digestive tolerability in various populations.

Key Adverse Reactions and Categories

Adverse reactions linked to Fibrasol or its core component (resistant maltodextrin/soluble corn fiber) are predominantly localized to the gastrointestinal system. These effects are often transient, may be dose-dependent, and are frequently reported during the initiation of fiber intake.

System-Organ Class Common Reactions Serious Reactions
Gastrointestinal Flatulence (Gas), Abdominal Bloating, Mild Abdominal Discomfort/Cramping None commonly documented
Immune System None commonly documented Rare hypersensitivity reactions (e.g., in occupational exposure)

Safety Considerations and Limitations

  • Dose-Related Patterns: Studies often indicate high digestive tolerability, with adverse gastrointestinal effects typically diminishing at moderate consumption levels (up to approximately 30 grams per day) compared to other fiber types. Higher intakes may increase the risk of temporary discomfort.
  • General Safety Notes: Adequate fluid intake is important when consuming any soluble fiber product to maintain safety and efficacy. Safety data does not indicate serious drug-like adverse events typically associated with prescription medicines.

Fibrasol is considered well-tolerated as a soluble fiber ingredient in food and dietary supplements, with a safety profile mainly characterized by minor, self-limiting digestive issues, particularly when introducing the product or using high doses. Formal drug-style safety restrictions are not applicable to its use as a dietary component.

Overdose and Emergency Response

Overdose and When to Seek Help

The ingredient in Fibrasol is a type of soluble dietary fiber. While official regulatory documents do not define a specific clinical overdose syndrome for this fiber, taking an excessive amount, or rapidly increasing intake, may lead to pronounced gastrointestinal symptoms. These manifestations are generally a result of high bulk-forming action and increased gas production.

Overdose Manifestations
Gastrointestinal discomfort: Severe abdominal bloating, excessive gas (flatulence), and cramping.
Altered bowel function: Significant and persistent constipation or, conversely, loose stool and diarrhea.
Dehydration: Increased fluid demand and potential for dehydration, especially if fluid intake is not sufficient.

Required Emergency Actions and Medical Attention

While most symptoms of excessive fiber intake are uncomfortable but not life-threatening, urgent medical attention is required for signs of a severe gastrointestinal complication. The most serious concern is the risk of a bowel (intestinal) obstruction or severe allergic reaction, which necessitates immediate care.

Seek immediate emergency medical help if you experience:

  • Severe, persistent abdominal pain.
  • Nausea, vomiting, or a high fever.
  • Complete inability to pass gas or stool (signs of a potential blockage).
  • Difficulty swallowing or breathing, which could indicate an allergic reaction.

In all other cases of discomfort, discontinuing use and increasing fluid intake typically relieves symptoms. If discomfort persists, consult with a healthcare professional to adjust your fiber intake.

Therapeutic Uses of Fibrasol

Targeting Chronic and Occasional Constipation

Fibrasol is commonly used to help with symptoms related to infrequent and unpredictable movements, covering both occasional episodes and persistent chronic idiopathic constipation. The core therapeutic benefit supports predictable regularity, which may assist with easing the overall symptom burden and contributes to easing distress related to abdominal discomfort and the preoccupation associated with irregular function. This bulk-forming agent is considered relevant in contexts involving certain distressing symptoms of chronic constipation.

Improving Stool Consistency and Evacuation Comfort

This therapy is relevant for easing the physical quality of stools, is applied in addressing excessive straining, and assisting in the maintenance of consistency, which contributes to improved comfort in situations related to irritative states such as hemorrhoids and anal fissures. Beyond digestive relief, Fibrasol may be used to help manage elevated total cholesterol and LDL cholesterol levels, and also assists with blood glucose control as an adjunctive measure.

“This supportive therapeutic action helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Supportive Relief for Constipation and Straining

Fibrasol is commonly used to help address symptom clusters that interfere with daily comfort, namely infrequent bowel movements, difficulty in passing stool, and associated physical straining. It supports general well-being during symptomatic phases related to organ-specific functional stress in conditions involving recurrent or episodic manifestations.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Fibrasol (Fenofibrate/Fenofibric Acid)

Official regulatory documents define specific populations for whom the use of Fibrasol is strictly restricted or contraindicated, based primarily on the patient's existing health status, particularly organ function.

Populations Who Must Not Use Fibrasol (Contraindications)

Condition/Status Eligibility Status
Severe Renal Impairment (including dialysis) Contraindicated
Active Liver Disease (including unexplained persistent liver function abnormalities) Contraindicated
Pre-existing Gallbladder Disease Contraindicated
Known Hypersensitivity to fenofibrate, fenofibric acid, or components Contraindicated
Nursing Mothers (Lactation) Contraindicated

Other Eligibility Considerations

  • Mild-to-Moderate Renal Impairment: Use is restricted and requires a dose reduction to avoid risk. High doses must be avoided.
  • Pediatric Patients: The safety and efficacy of Fibrasol have not been established in this age group.
  • Geriatric Patients: Dose selection requires careful consideration of the patient's renal function, which often declines with age.

These official eligibility constraints ensure that the medicine is reserved for the target adult population who do not have specified, severe impairments of the kidneys, liver, or gallbladder, and are not in a state (like lactation) that is prohibited by the regulatory labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Fibrasol (Psyllium Hydrophilic Mucilloid) is primarily defined by a physical, non-systemic effect on the absorption of co-administered oral medications. Regulatory information does not document any systemic interactions involving metabolic enzymes, such as the cytochrome P450 system, or drug transporters, due to the minimal absorption of Psyllium.

Pharmacokinetic Interaction and Required Timing

Co-administration with other oral medicinal products may cause a reduction in the enteral absorption and subsequent systemic exposure of those products. This is attributed to the physical sequestration of medicinal substances within the viscous, hydrophilic bulk created by Fibrasol in the gastrointestinal tract.

To mitigate this pharmacokinetic interference, regulatory documents mandate a mandatory timing separation:

Constraint Requirement as documented in official labeling
Timing Separation Other oral medicinal products must be taken at least two hours before or two hours after the administration of Fibrasol.

Specific medicines whose absorption and effectiveness are officially noted as potentially impacted include Lithium, Digoxin, Carbamazepine, and Coumarin derivatives (e.g., Warfarin). There are no general contraindications based on interaction risk alone.

Formulation-Specific Restrictions

Some sugar-free formulations of this product contain Phenylalanine, which constitutes a dietary restriction for individuals with Phenylketonuria (PKU). No other clinically significant interactions with food, alcohol, or herbal products are officially documented.

Mechanism of Action

How Fibrasol Works

The mechanism of action for Fibrasol (Psyllium Hydrophilic Mucilloid) is strictly physical, localized exclusively within the gastrointestinal lumen, and does not involve systemic absorption or interaction with cellular protein targets like receptors or enzymes. The action initiates with the substance's profound hydrophilic capacity, causing rapid water absorption from the intestinal contents. This process transforms the mucilloid into a cohesive, viscous gel-like mass.

This colloidal action modulates the fecal rheology (consistency), allowing the contents to maintain hydration. The resulting significant increase in intraluminal volume physically stretches and distends the colonic wall, thereby stimulating mechanoreceptors linked to the myenteric plexus. This mechanical signal triggers the natural peristaltic reflex, which increases propulsive motility and modulates the overall intestinal transit time. The effectiveness of this bulk-forming mechanism is absolutely dependent on the availability of sufficient exogenous fluid for the mucilloid to fully hydrate and swell.

Dosage and Administration Information

How to Use Fibrasol

Fibrasol, which contains Psyllium Hydrophilic Mucilloid, is administered through the oral route as a powder or granules that must be mixed with a liquid before consumption. The medication is classified as a bulk-forming agent, which necessitates specific preparation steps to ensure proper use. This regimen focuses on the quantity of fluid required, the frequency of administration, and timing separation from other therapies.

Administration and Dosing Principles

Administration requires mixing the measured dose with at least 8 ounces (a full glass) of water or other fluid. The mixture should be stirred quickly and consumed immediately, often followed by an additional glass of liquid. Dosing is flexible concerning meals; the product can be taken either before or after food, which allows for integration into a daily routine. Effects on intestinal function typically become noticeable within 12 to 72 hours of administration.

Standard Regimen and Population Adjustments

The standard adult dose (for individuals 12 years and older) is one serving, initiating at once daily and increasing as necessary up to a maximum frequency of three times per day. For children aged 6 to under 12 years, the labeled regimen instructs the use of half the adult dose, also taken up to three times daily. A critical constraint on usage is the mandatory two-hour separation from all other oral prescription medicines. This rule exists to prevent the fiber from interfering with the systemic absorption of other co-administered drugs.

Recent Clinical Evidence

Fibrasol: Recent Clinical Evidence

Evidence for Bowel Regulation and Chronic Constipation

Research into Fibrasol (Psyllium Hydrophilic Mucilloid) was studied for use in regulating intestinal function, primarily involving Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies focus on adult populations experiencing conditions characterized by fluctuating or episodic manifestations of chronic constipation. Researchers monitored key outcomes related to physical discomfort, such as changes in stool frequency and consistency. Research monitored patient-reported outcomes related to the severity of straining.

Trials described patterns in the measurements of these physiological changes. The evidence contributes to understanding symptom patterns, and research does not determine whether an individual will respond similarly.

What remains uncertain is the full profile of use over very extended periods. The majority of the core regulatory evidence features follow-up durations that were limited to short or intermediate terms, generally not exceeding three months. Therefore, long-term effects are not fully established, and there is limited specific information regarding how the medicine performs across varied severity levels of chronic constipation.

Research on Stool Quality and Adjunctive Digestive Support

Fibrasol was observed in research contexts involving fluctuating or unstable symptoms in situations associated with increased discomfort, such as those that may occur with hemorrhoids and anal fissures. The evidence base here includes observational studies and secondary analyses from larger trials. Research examined stool quality, specifically monitoring outcomes linked to inflammatory or irritative states where outcomes monitoring physiological strain were relevant.

Research noted that while stool quality was evaluated, the studies focused mainly on measuring changes in stool properties. Direct efficacy on the healing or recurrence of the underlying irritative conditions (fissures, hemorrhoids) is not the focus of the primary evidence.

Studies on Cholesterol and Blood Glucose Endpoints

Separate, high-quality research, including multiple RCTs and Meta-analyses, was conducted to study Fibrasol's influence on systemic markers. This research examined outcomes related to systemic or functional imbalance in adult populations presenting with mild-to-moderate elevated cholesterol levels. Key outcomes monitored included shifts in total and LDL cholesterol levels over intermediate to long-term observation periods.

Multiple long-term trials reported how the measured markers evolved in the observed populations. Similarly, research examined Fibrasol in studies that monitored changes in postprandial (after-meal) blood glucose levels over defined time intervals.

The existing evidence describes Fibrasol as an adjunctive measure in the research context, and studies do not characterize its use as a standalone therapy. The evidence quality varies across studies, and while short-term changes in glucose levels was observed in some studies, the long-term durability of these reported changes is not fully established.

Research Gaps and Areas of Uncertainty

The primary research gap centers on the follow-up durations were limited in many constipation studies, meaning the full profile of use beyond a few months remains unclear. Subgroup findings are uncertain or limited for several populations. Furthermore, research noted that an association was observed in some studies between use and changes in stool quality metrics, but the research does not characterize the effect on the underlying disease progression itself. Therefore, the full scope of use relies on understanding these evidence limitations and areas where data are still emerging.

Key Studies & References

  1. Psyllium Hydrophilic Mucilloid: Drug Monograph and Pharmaceutical Properties (DrugBank)

Frequently Asked Questions (FAQ)

Common questions about Fibrasol (FAQ)

Q: Can Fibrasol be taken with common over-the-counter pain relievers?

Official labeling advises separating Fibrasol from all other oral medicines, including over-the-counter (OTC) products like pain relievers.

Official guidance specifies this timing separation is at least two hours. The purpose is to help avoid the bulk-forming agent from physically interfering with the absorption of the other medication.

Q: What is the difference between Fibrasol and other similar medications mentioned online?

Fibrasol is formally categorized as a bulk-producing laxative. It works by a gentle, purely mechanical process in the digestive system by increasing bulk and hydration.

This mechanism is distinct from other types of laxatives, such as stimulant laxatives, which function through chemical irritation of the intestinal walls to promote movement.

Q: Can teenagers or children use Fibrasol?

Official product labeling provides specific dosing regimens for children aged 6 to under 12 years, as well as for teenagers and adults 12 years and older when managing occasional constipation.

Regulatory information notes that use in children under the age of 6 requires consultation with a physician.

Q: Does taking Fibrasol affect my liver or kidney function tests?

The active ingredient in Fibrasol, Psyllium Hydrophilic Mucilloid, is minimally absorbed by the body into the bloodstream. Because of this localized action, the product does not typically interact with metabolic enzymes in the liver or kidneys.

Regulatory information indicates its effects are confined primarily to the digestive tract.

Q: Can Fibrasol be used at the same time as vitamin supplements?

The product's mechanism of action involves creating a hydrophilic bulk that can physically reduce the absorption of other substances. For this reason, regulatory documents specify a separation of at least two hours for all other oral products, including vitamin supplements and herbal products.

Q: How does Fibrasol's mechanism of action differ from non-drug therapies?

Fibrasol's effect is achieved through a physical, mechanical action: the rapid absorption of water in the intestine to create a soft, viscous gel. While similar to the action of dietary fiber, Fibrasol is a concentrated source of this hydrophilic material.

This physical bulking action is key to promoting the natural peristaltic reflex.

Q: What are the most serious, but rare, side effects reported for Fibrasol?

The safety profile is generally associated with mild gastrointestinal issues. However, official information does note that rare hypersensitivity reactions have been reported.

These severe reactions may include symptoms such as swelling of the face or throat, difficulty breathing, or hives.

Q: Does Fibrasol contain gluten, lactose, or common allergens?

The active ingredient, Psyllium, is naturally free of components like gluten and lactose. However, some specific product formulations may contain inactive ingredients like phenylalanine or flavorings.

The presence of common allergens depends entirely on the specific product brand and its complete formulation.

Q: Can Fibrasol be used by women who are pregnant or breastfeeding?

Regulatory information states that controlled studies of Fibrasol's use in pregnant women are unavailable. Official guidance indicates that the decision to use Fibrasol during pregnancy or breastfeeding is based on a clinical assessment by a healthcare provider.

Q: What kind of specialist usually prescribes Fibrasol?

Fibrasol is classified as an Over-The-Counter (OTC) product, which means a prescription is not necessary to purchase it.

It is classified as an OTC product intended for the regulatory indication of occasional constipation.

Q: Is it okay to take Fibrasol with a cup of coffee or tea?

Official administration guidelines require mixing the measured dose with at least eight ounces of liquid, such as water or juice, and consuming it quickly.

While documentation does not explicitly prohibit coffee or tea, for proper hydration and effectiveness, it is necessary to use the required minimum amount of liquid for mixing.

Q: Does Fibrasol interact with oral contraceptives or other hormonal medications?

Because Fibrasol can physically interfere with the absorption of other substances, official regulatory documents advise separating it from all other oral prescription medicines by at least two hours.

This separation is advised to help mitigate the risk that Fibrasol's physical bulk may interfere with the absorption of the other medication.

Q: What happens if I miss a scheduled dose of Fibrasol?

Fibrasol is generally intended for use on an as-needed basis for occasional constipation. Regulatory guidelines state that if a dose is missed, it is generally to be skipped.

Users should not attempt to compensate by taking double or extra doses.

Q: Why is Fibrasol sometimes described as helping with 'X condition' when its label is for 'Y condition'?

Official documents and regulatory data confirm that the active ingredient in Fibrasol has been studied in clinical research contexts for potential adjunctive uses.

These studies have examined its influence on systemic markers, such as cholesterol levels and postprandial blood glucose endpoints, leading to broader discussions about its function.

Q: Is Fibrasol safe to take if I have a history of heart issues?

Official guidance indicates that the soluble fiber in the active ingredient may be included as part of a diet low in saturated fat and cholesterol, which helps reduce the risk of Coronary Heart Disease (CHD).

This is relevant when discussing the context of heart issues, as described in official documents.

Q: Is the research evidence for Fibrasol considered strong by medical authorities?

Official documents and research overviews indicate that the active ingredient has been the subject of high-quality studies, including Randomized Controlled Trials (RCTs) and systematic meta-analyses.

However, these documents also note that many constipation studies have had limited follow-up durations, meaning the long-term effectiveness profile remains an area of ongoing research.

Q: Does Fibrasol have an addictive potential or cause withdrawal symptoms?

Regulatory documents include a statement noting the potential for dependence.

This information is provided to caution that the frequent or prolonged use of a laxative preparation may lead to a person relying on the laxative for bowel function.

Q: Is there a known maximum length of time Fibrasol should be used?

Official regulatory documents state that use should not exceed a period longer than 7 days without consulting a doctor.

Constipation that persists beyond one week may signal a more serious underlying condition that requires medical evaluation.

Q: What is the difference between the 'active ingredient' and 'inactive ingredients' in Fibrasol?

The active ingredient, Psyllium Hydrophilic Mucilloid, is the component responsible for the drug's intended function—the bulk-forming action that regulates bowel movements.

Inactive ingredients are added solely for formulation purposes, such as to provide flavor, color, or aid in the manufacturing process.

How should Fibrasol be stored and disposed of?

How to Store and Dispose of Fibrasol

Fibrasol (psyllium husk powder) must be stored according to regulatory labeling to maintain its stability and effectiveness. Official requirements mandate storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and not exceeding 30 C.

The container must be kept tightly closed to provide necessary protection from moisture and humidity, which is essential given the powder's water-absorbing nature. The product must also be stored out of the reach of children.

For disposal, the product is not recommended for flushing down the toilet or sink. Unused or expired Fibrasol should be taken to a drug take-back program or disposed of in the household trash after being mixed with an undesirable substance and placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fibrasol found in:

A-Z Index: